Ipsen enters deal with Photocure to commercialize Hexvix

28 September 2011

French drugmaker Ipsen (Euronext: IPN) has entered into a partnership with Norway-based Photocure (OSE: PHO) to commercialize the latter’s flagship product Hexvix, for the diagnosis and resection of bladder cancer, worldwide except in the USA and the Nordic region.

Additionally, to capitalize on the untapped US market opportunity, Photocure plans to launch the product, approved as Cysview in the USA, through its own commercial operations. The new strategy will maximize the potential of Hexvix on a global basis.

Upfront outlay of 19 million euros

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK